-
Innovation Ranking
NewInnovation Ranking – Graybug Vision Inc
CalciMedica Inc (CalciMedica), formerly Graybug Vision Inc, is a clinical-stage pharmaceutical company that develops next-generation products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. Its pipeline portfolio comprise GB-102, GB-601, GB-701, GB-501 and GB-401.The company’s lead candidate includes GB-102, a clinical-stage depot formulation of sunitinib malatcontains, which is a single small molecule compound that blocks multiple pathogenic angiogenesis pathways included in choroidal neovascularization that causes neovascular or wet age-related macular degeneration. It develops products for...
-
Product Insights
NewLikelihood of Approval Analysis for Vision Disorders
Overview How likely is it that the drugs in Vision Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vision Disorders Overview Vision disorders are characterized by poor or unclear vision...
-
Sector Analysis
NewAutomotive Vision Systems Market Trends, Sector Overview and Forecast to 2028
Automotive Vision Systems Market Report Overview The automotive vision systems market size was estimated at 709.3 million units in 2023. The market will grow at a CAGR of more than 1% during 2023-2028. Increased consumer awareness regarding road safety and a desire for advanced features are driving the growth of vision system technologies. The Asia-Pacific region had a significant share in the automotive vision systems market. Automotive Vision Systems Market Outlook 2023-2028 (Million Units) Buy the Full Report for Additional...
-
Product Insights
NewLikelihood of Approval Analysis for Retinal Degeneration
Overview How likely is it that the drugs in Retinal Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retinal Degeneration Overview Retinal degeneration refers to a group of diseases that...
-
Product Insights
NewLikelihood of Approval Analysis for Diabetic Retinopathy
Overview How likely is it that the drugs in Diabetic Retinopathy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diabetic Retinopathy Overview Diabetic retinopathy is a complication of diabetes that affects...
-
Product Insights
NewLikelihood of Approval Analysis for Age Related Macular Degeneration
Overview How likely is it that the drugs in Age Related Macular Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Age Related Macular Degeneration Overview Macular degeneration, also known as...
-
Product Insights
NewLikelihood of Approval Analysis for Open-Angle Glaucoma
Overview How likely is it that the drugs in Open-Angle Glaucoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Open-Angle Glaucoma Overview Open-angle glaucoma is a chronic eye condition characterized by...
-
Product Insights
NewLikelihood of Approval Analysis for Proliferative Diabetic Retinopathy (PDR)
Overview How likely is it that the drugs in Proliferative Diabetic Retinopathy (PDR) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Proliferative Diabetic Retinopathy (PDR) Overview Proliferative diabetic retinopathy (PDR) is...
-
Product Insights
Green Vision-Brasov Solar PV Park – 1
Green Vision-Brasov Solar PV Park - 1 is a solar PV project located in Brasov, Romania. The project is owned by Hareon Solar Technology Co Ltd; Jiangsu Sunshine Group Co Ltd and is developed by Conecon GmbH; Green Vision Seven SRL; Hareon Solar Technology Co Ltd. The project is currently partially active. Empower your strategies with our Green Vision-Brasov Solar PV Park - 1 report and make more profitable business decisions. Note: This is an on-demand report that will be...